Junyuan X. Qi

No. 288 Nanjing Road
Xiaobailou, 300051, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia.

XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia.

Journal: The Journal of clinical investigation

Published: September 01, 2026

LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

Journal: Frontiers in pharmacology

Published: February 18, 2026

Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.

Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 10, 2025

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Journal: European journal of haematology

Published: October 10, 2025

Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.

Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.

Journal: Leukemia research

Published: August 14, 2024

Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.

Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.

Journal: Cancer

Published: July 02, 2024

Patients with acquired pure red cell aplasia respond to PI3Kδ inhibitor rapidly.

Patients with acquired pure red cell aplasia respond to PI3Kδ inhibitor rapidly.

Journal: American journal of hematology

Published: March 14, 2024

Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China.

Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China.

Journal: Clinical pharmacology in drug development

Published: October 12, 2023

Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.

Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 24, 2023

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma.

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma.

Journal: Scientific reports

Published: July 11, 2023

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma.

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma.

Journal: Experimental and therapeutic medicine

Published: May 12, 2023

B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.

B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.

Journal: ESC heart failure

Published: March 15, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026